logo
Where Will Lucid Group Be in 10 Years?

Where Will Lucid Group Be in 10 Years?

Yahoo4 hours ago

Lucid's new vehicles will boost sales and profits.
The future of Lucid might not e building cars at all.
10 stocks we like better than Lucid Group ›
The next few years should be pivotal for Lucid Group (NASDAQ: LCID). The company recently onboarded a new CEO, started production on its new Gravity SUV platform, and announced several new vehicles, the first of which is expected to start production in late 2026.
But what about the next 10 years? Keeping an eye on the long term is critical for investors. And the decade ahead might hold more surprises than you'd expect.
Last week, Lucid opened a new research and development hub in Arizona. The company had previously purchased the facilities from Nikola Corporation, a defunct EV start-up. "These new facilities provide Lucid with immediate and substantial capacity for advanced manufacturing activities, as well as developing product innovations and testing components and systems," a company representative noted.
There was a small nugget of surprise in the announcement, however, that had nothing to do with the facilities themselves. "Inside of this building are the first prototypes of a midsize SUV that will be priced under $50,000," one reporter revealed. Lucid's new CEO, Marc Winterhoff, confirmed that the location would be responsible for building the first iterations of these new models, saying that there will be "a pilot line where we build the first vehicles for our midsized platform."
These revelations were interesting because they are the first real updates we've gotten about these new models in many months. Lucid began teasing three new mass market vehicles last summer, but updates have been hard to come by. Earlier this year, Lucid's former CEO stressed that these new models will finally allow the company to "compete directly with Tesla." He predicted the company would eventually sell more than 1 million vehicles per year by the early 2030s. But apart from optimistic comments like these, details have been scarce.
Recent surveys show that a big majority of Americans are aiming to spend less than $50,000 on their next car purchase. To gain scale and reach profitability, getting these new affordable models to market will be critical for Lucid. We still don't have enough details to be confident in management's production timeline of late 2026. But expect these new models to be the centerpiece of Lucid's growth over the next two to five years. Looking beyond this time frame, however, Lucid's growth may not include selling vehicles at all.
Making cars today involves significantly more technology than the past, especially when it comes to software. Complex software architectures are required not only for basic vehicle operation, but also emissions controls, safety features, and self-driving capabilities. Currently, many carmakers outsource much of this software stack to a list of third-party vendors. That adds significant cost and complexity. When Volkswagen agreed to invest $5.8 billion into a joint venture with EV maker Rivian, the focus wasn't making cars, but in using Rivian's unique software stack to streamline Volkswagen's production timelines.
As a tech-focused EV maker, Lucid has also developed its own software stack, one that Lucid's management team believes could revolutionize the industry. The company has already begun licensing its technology to other automakers, helping them reduce manufacturing costs and improve vehicle efficiency. Lucid's CEO recently stated that most of Lucid's long-term business should come from tech licensing, not car manufacturing. "I'd love it to be 20-80. Twenty percent doing cars, 80% licensing," he revealed. "Because the vision I have for Lucid is: Just as there's an Intel inside your laptop, there's a Lucid inside a Honda or a Toyota."
Making cars today simply provides Lucid with an ability to showcase this technology. And given that software typically has higher profit margins and recurring revenues than car manufacturing, this segment of the business is very promising. A decade from now -- at least if Lucid's management team gets its way -- expect Lucid to be more of a software business than a manufacturer.
Before you buy stock in Lucid Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!*
Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intel. The Motley Fool recommends Volkswagen Ag and recommends the following options: short August 2025 $24 calls on Intel. The Motley Fool has a disclosure policy.
Where Will Lucid Group Be in 10 Years? was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Yahoo

time38 minutes ago

  • Yahoo

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company's nomlabofusp clinical development program for the treatment of Friedreich's Ataxia on Monday, June 23, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13754491 or click on this link and request a return call. Following the live event, an archived webcast will be available on the 'Events & Presentations' page of the Larimar website. About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: Forward-Looking StatementsThis press release contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar's ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar's planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding potential for accelerated approval or accelerated access and time to market and overall development plans and other matters regarding Larimar's business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar's product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar's nomlabofusp development strategy; the potential impact of public health crises on Larimar's future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar's ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp's manufacturing process; Larimar's ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar's ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar's management's views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law. Investor Contact:Joyce AllaireLifeSci Advisorsjallaire@ 915-2569 Company Contact:Michael CelanoChief Financial Officermcelano@ 414-2715Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Morgan Stanley Maintained a Buy Rating on Wix.com (WIX), Kept the PT Unchanged
Morgan Stanley Maintained a Buy Rating on Wix.com (WIX), Kept the PT Unchanged

Yahoo

time38 minutes ago

  • Yahoo

Morgan Stanley Maintained a Buy Rating on Wix.com (WIX), Kept the PT Unchanged

Ltd. (NASDAQ:WIX) is one of the 11 Best Tech Stocks to Buy On the Dip. On June 13, analyst Elizabeth Porter from Morgan Stanley maintained a Buy rating on Ltd. (NASDAQ:WIX) with a price target of $207. The rating comes after the company released its Q1 2025 results in May. The company delivered a robust start to the year with Q1 total bookings of $511 million up 12% year-over-year. The revenue for the quarter totaled $474 million, exceeding expectations and reflecting 13% growth. Management noted this to be driven by accelerated Self Creators growth and momentum in Studio adoption. A content marketing website showing the audience reach of the company's products. Analyst Porter appreciated the robust performance of Ltd. (NASDAQ:WIX) across key indicators including bookings, revenue, operating margins, and free cash flow. Porter noted this growth suggests a solid demand and counters concerns about competition and AI displacement risks. Management of Ltd. (NASDAQ:WIX) maintained a full-year booking outlook at $2.025 billion to $2.060 billion reflecting an 11% to 13% increase year-over-year. The analyst acknowledged the outlook to be conservative due to macroeconomic challenges, particularly in the Business Solutions segment. While we acknowledge the potential of WIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Marin Software Incorporated Receives Nasdaq Notification Regarding Delisting From Nasdaq
Marin Software Incorporated Receives Nasdaq Notification Regarding Delisting From Nasdaq

Business Wire

time43 minutes ago

  • Business Wire

Marin Software Incorporated Receives Nasdaq Notification Regarding Delisting From Nasdaq

SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marin Software Incorporated (NASDAQ: MRIN) ('Marin,' 'we,' 'our,' or the 'Company'), a provider of digital marketing software for performance-driven advertisers and agencies, announces that, on June 17, 2025, the Company received a notice (the 'Notice') from the Listing Qualifications Department of the Nasdaq Stock Market LLC ('Nasdaq') stating that Nasdaq had determined that the Company did not provide a definitive plan evidencing its ability to achieve compliance with the Nasdaq Listing Rule 5250(c)(1) (the 'Listing Rule'), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the 'SEC'). The Company had previously submitted a letter to Nasdaq requesting an exception to extend the Company's listing on Nasdaq for 180 days, until October 13, 2025. As a result of Nasdaq's determination, the Notice states that (i) the Company's request for continued listing on Nasdaq was denied; (ii) the Company's securities will be delisted from Nasdaq; (ii) trading of the Company's common stock will be suspended at the opening of business on June 26, 2025; and (iii) a Form 25-NSE will be filed with the SEC, which will remove the Company's securities from listing and registration on Nasdaq, unless the Company appeals these determinations. The Notice further states that the Company continues to be delinquent in the timely filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, as previously communicated by Nasdaq on April 16, 2025 and May 21, 2025, respectively. The Company does not expect to appeal Nasdaq's determinations and expects Nasdaq to file a Form 25-NSE (Notification of Removal from Listing) with the SEC to remove the Company's common stock from listing and registration on Nasdaq. Further, the Company does not currently intend to apply for its common stock to be traded on any of the markets operated by the OTC Markets Group Inc. due to the associated costs and in light of both the previously announced potential transaction the Company is currently exploring whereby a private equity firm would acquire substantially all of the assets of the Company, which may be through a voluntary reorganization transaction (the 'Potential Transaction'), as well as the voluntary dissolution and liquidation of the Company (the 'Dissolution') that was previously approved by the Company's stockholders. There can be no assurance that the Potential Transaction will be entered into or ultimately be successful, and the Company may abandon pursuing the Potential Transaction and instead pursue the Dissolution as previously described in the Company's Definitive Proxy Statement on Schedule 14A filed with the SEC on May 7, 2025 (the 'Proxy Statement'). For additional information regarding the Nasdaq notification and related terms, please see the Current Report on Form 8-K that the Company filed with the SEC today, which is available at Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words 'believe,' 'anticipate,' 'estimate,' 'expect,' 'intend,' 'plan,' 'project,' 'prospects,' 'outlook,' and similar words or expressions, or future or conditional verbs such as 'will,' 'should,' 'would,' 'may,' and 'could' are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors. Marin disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise, except as required by applicable law. Actual results may differ from those indicated by such forward-looking statements the risks described under 'Risk Factors' in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024, the Proxy Statement under the heading 'Risk Factors to be Considered by Stockholders in Deciding Whether to Approve the Plan of Dissolution,' and the Company's future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Marin as of the date hereof. The Company disclaims any obligation to update any forward-looking statements, except as required by law.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store